Regencell Bioscience (RGC)
Develops standardized traditional Chinese medicine formulas for ADHD and autism spectrum disorder.
RGC Resources Q3 Earnings Call Highlights
RGC Resources NASDAQ: RGCO reported fiscal 2026 third-quarter net income of about $550,000, or $0.05 per diluted share, as higher margins supported results despite uneven weather patterns, increased operating expenses and the loss of a large industrial customer.
RGC Resources, Inc. Reports Third Quarter Earnings
ROANOKE, Va., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated earnings of $559,000, or $0.05 per diluted share, for the third quarter ended June 30, 2026, compared to $538,000, or $0.05 per diluted share, for the third quarter ended June 30, 2025. Operating margin for the third quarter was $757,000 higher than the equivalent period a year earlier aided by higher non-gas base rates that became effective January 1, 2026. Operating expenses were higher by a similar amount resulting in a nominal decline in operating earnings.
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.
RGC Resources, Inc. Declares Quarterly Dividend
ROANOKE, Va., June 29, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2175 per share on the Company's common stock. The dividend will be paid on August 3, 2026 to shareholders of record on July 17, 2026. This is the Company's 329th consecutive quarterly cash dividend.
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) and certain officers. The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limit
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, June 23, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and certain of its officers.
Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell is a purported early-stage bioscience company.For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Firm is Investigating th.
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
New York, New York--(Newsfile Corp. - June 23, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors
LOS ANGELES, June 23, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regencell Bioscience Holdings Limited, (“Regencell” or the "Company") (NASDAQ: RGC) investors of a class action on behalf of investors that bought securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell investors have until June 23, 2026 to file a lead plaintiff motion.
RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm
NEW YORK, June 23, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC). Shareholders who purchased shares of RGC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit
NEW YORK, June 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"), of the important June 23, 2026 lead plaintiff deadline. So what: If you purchased Regencell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role
Bragar Eagel and Squire, P. C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Regencell (RGC) To Contact Him Directly To Discuss Their Options If you purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025 and would like to discuss your legal rights, call Bragar Eagel and Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 23, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC),.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC
Were Regencell's Boilerplate Risk Warnings Adequate? Lawsuit Alleges $14 Billion Company Used Generic Volatility Disclaimers to Mask Specific Market Manipulation Vulnerability Were Regencell's Boilerplate Risk Warnings Adequate? Lawsuit Alleges $14 Billion Company Used Generic Volatility Disclaimers to Mask Specific Market Manipulation Vulnerability
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
New York, New York--(Newsfile Corp. - June 21, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Regencell (RGC) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/23/2026
RGC DEADLINE: The Gross Law Firm Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline
NEW YORK, June 19, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC).
Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
New York, New York--(Newsfile Corp. - June 18, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC
Alert: Claims Focus on Alleged Misrepresentations About Regencell's $1 Million R&D Budget Versus $14 Billion Market Valuation NEW YORK, June 18, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities of a pending securities class action. THE CASE: A class action was filed, seeking to recover damages for investors who purchased Regencell securities between October 28, 2024 and October 31, 2025.